Table 2. Primary treatment and response in patients with extranodal natural killer (NK)/T-cell lymphoma.
| Treatment | Low-CRP group, n (%) | High-CRP group, n (%) | P |
| Patients treated | 104 (94.5) | 73 (97.3) | 0.584 |
| Treatment modalities | 0.092 | ||
| CT followed by RT | 71 (64.5) | 40 (53.3) | |
| CT alone | 24 (21.8) | 30 (40.0) | |
| RT alone | 3 (2.7) | 1 (1.3) | |
| Surgery followed by CT | 6 (5.5) | 2 (2.7) | |
| Best supportive care | 6 (5.5) | 2 (2.7) | |
| Chemotherapy regimens | 0.986 | ||
| CHOP or CHOP-like | 12 (11.9) | 8 (11.1) | |
| EPOCH | 38 (37.6) | 25 (34.7) | |
| ATT | 22 (21.8) | 17 (23.6) | |
| GEMOX+L-asp | 27(26.7) | 21 (29.2) | |
| SMILE | 2 (2.0) | 1 (1.4) | |
| Complete remission | 86 (82.7) | 39 (53.4) | <0.001 |
Abbreviations: CRP: C-reactive protein; CT: chemotherapy; RT: radiotherapy; CHOP: cyclophosphamide+doxorubicin+vincristine+prednisone; EPOCH: etoposide+doxorubicin+vincristine+cyclophosphamide+prednisone; ATT: alternating triple therapy (CHOP-B, cyclophosphamide+doxorubicin+vincristine+bleomycin+prednisone; IMVP-16, ifosfamide+methotrexate+etoposide; DHAP, dexamethasone+cisplatin+cytarabine); GEMOX+L-asp: gemcitabine+oxaliplatin+L-asparaginase; SMILE: dexamethasone+methotrexate+ifosfamide+L-asparaginase+etoposide.